<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0003674'>Oxidative stress</z:mp> is produced under diabetic conditions and possibly causes various forms of tissue damage in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to examine the involvement of <z:mp ids='MP_0003674'>oxidative stress</z:mp> in the progression of pancreatic <z:hpo ids='HP_0006279'>beta-cell dysfunction</z:hpo> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and to evaluate the potential usefulness of <z:chebi fb="11" ids="22586">antioxidants</z:chebi> in the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>We used diabetic C57BL/KsJ-db/db mice, in whom <z:chebi fb="11" ids="22586">antioxidant</z:chebi> treatment (<z:chebi fb="0" ids="28939">N-acetyl-L-cysteine</z:chebi> [NAC], <z:chebi fb="122" ids="21241">vitamins C</z:chebi> plus E, or both) was started at 6 weeks of age; its effects were evaluated at 10 and 16 weeks of age </plain></SENT>
<SENT sid="3" pm="."><plain>According to an intraperitoneal <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test, the treatment with NAC retained <z:chebi fb="105" ids="17234">glucose</z:chebi>-stimulated insulin secretion and moderately decreased blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="122" ids="21241">Vitamins C</z:chebi> and E were not effective when used alone but slightly effective when used in combination with NAC </plain></SENT>
<SENT sid="5" pm="."><plain>No effect on insulin secretion was observed when the same set of <z:chebi fb="11" ids="22586">antioxidants</z:chebi> was given to nondiabetic control mice </plain></SENT>
<SENT sid="6" pm="."><plain>Histologic analyses of the pancreases revealed that the beta-cell mass was significantly larger in the diabetic mice treated with the <z:chebi fb="11" ids="22586">antioxidants</z:chebi> than in the untreated mice </plain></SENT>
<SENT sid="7" pm="."><plain>As a possible cause, the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> treatment suppressed <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in beta-cells without changing the rate of beta-cell proliferation, supporting the hypothesis that in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induced by <z:mp ids='MP_0003674'>oxidative stress</z:mp> causes reduction of beta-cell mass </plain></SENT>
<SENT sid="8" pm="."><plain>The <z:chebi fb="11" ids="22586">antioxidant</z:chebi> treatment also preserved the amounts of insulin content and insulin <z:chebi fb="2" ids="33699">mRNA</z:chebi>, making the extent of insulin degranulation less evident </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, expression of pancreatic and duodenal homeobox factor-1 (PDX-1), a beta-cell-specific transcription factor, was more clearly visible in the nuclei of islet cells after the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> treatment </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, our observations indicate that <z:chebi fb="11" ids="22586">antioxidant</z:chebi> treatment can exert beneficial effects in <z:mp ids='MP_0002055'>diabetes</z:mp>, with preservation of in vivo beta-cell function </plain></SENT>
<SENT sid="11" pm="."><plain>This finding suggests a potential usefulness of <z:chebi fb="11" ids="22586">antioxidants</z:chebi> for treating <z:mp ids='MP_0002055'>diabetes</z:mp> and provides further support for the implication of <z:mp ids='MP_0003674'>oxidative stress</z:mp> in <z:hpo ids='HP_0006279'>beta-cell dysfunction</z:hpo> in <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>